OPTIMIZING NON-ADDICTIVE DRUG DELIVERY WORLDWIDE
IN THE MANAGEMENT OF PAIN AND CNS DISORDERS
Virpax Pharmaceuticals specializes in developing novel and proprietary drug-delivery systems across various pain and CNS disorder indications to enhance compliance and to optimize the efficacy of each product candidate.
Our transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to optimize the efficacy of our non-addictive pain management pipeline and our CNS disorder pipeline. Our goal is for each product candidate to become the standard of care in their respective Therapeutic sectors. Our business objective is to commercialize products that will be supported by respective medical societies, and advocacy groups, as well as be regarded by insurance companies, prescribers, pharmacists and hospitals.
Virpax® Pharmaceuticals (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.
NOVEL DRUG-DELIVERY SYSTEMS
We’re developing molecules with the MET to deliver treatment options for the management of:
Liposomal in Hydrogel encapsulation
Virpax uses a patented injectable liposomal hydrogel encapsulation to deliver a local anesthetic at the wound/incision site providing pain control for 96 hours.
We’re using liposomal hydrogel encapsulation to develop a local anesthetic for:
Topical spray film
Virpax uses a patented spray film technology to deliver drug molecules intended for localized administration without the messy handling or creams and gels.
We’re using the proprietary topical spray film technology to develop an anti-inflammatory agent to manage pain associated with:
Recent Media
[VIDEO] Virpax appears on 6abc Philadelphia
Mar 29, 2022
Prescribers, regulators, and patients all seek non-addictive treatment options to combat the opioid epidemic.
FDA takes steps aimed at fostering development of non-addictive alternatives to opioids for acute pain management lasting up to 30 days, in response to some form of tissue injury, such as trauma or surgery.
February 2022
The accelerating development of new treatments and devices are top six on the FDA priority list.
February 2022
OUR MISSION
Our mission is to use our proprietary delivery systems to optimize the efficacy of our non‑addictive pain and CNS disorder product candidates.
We want to provide healthcare professionals and patients with effective solutions to manage pain and neurological disorders worldwide.
OPTIMIZING DRUG-DELIVERY
In the Treatment of Pain and CNS Disorders
Envelta™
Molecular Envelope Enkephalin Powder
Envelta is an intranasal enkephalin powder formulation being studied to manage severe post cancer pain and non-cancer pain without the concerns of dependence, respiratory depression, and tolerance compared to morphine.
Probudur™
Injectable liposomal hydrogel Bupivacaine
Virpax will introduce its proprietary Probudur, a single injectable liposomal gel local anesthetic for postoperative pain management. Probudur will be the only liposomal gel bupivacaine with 96 hours of postoperative pain control; longer than any other liposomal bupivacaine.
Epoladerm™
Topical Diclofenac Spray Film
Epoladerm nonclinical studies have demonstrated improved drying times and less messy handling compared to topical gels/ointments. It’s an invisible application, therefore, more aesthetically appealing. Its pliable application allows for optimized use on contours of the knees.
